Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

December 1, 2019

Study Completion Date

January 31, 2021

Conditions
Endometriosis
Interventions
PROCEDURE

Surgical induction of endometriotic explants

"Surgical induction of endometriosis was done as: A 5-cm vertical midline incision was made and a distal segment 1 cm in length of the right uterine horn was resected. The segment was split longitudinally, and a 5 X 5 mm piece was sectioned.~This piece of uterine tissue was transplanted without removing the myometrium onto the inner surface of the right abdominal wall with the serosal surface apposed and secured with single nonabsorbable 5-0 polypropylene suture at the middle to the abdominal wall. The abdominal incision was closed in two layers~Drug administration:~Vehicle treatment (1 mL/kg/day saline) was administered orally to the control group with the gavage methodology. Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the rats in the study for 28 days postoperatively"

Trial Locations (1)

33343

Mersin University, Mersin

All Listed Sponsors
lead

Mersin University

OTHER

NCT04844996 - Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis | Biotech Hunter | Biotech Hunter